Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have received an average rating of "Moderate Buy" from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have commented on the stock. Oppenheimer reissued an "outperform" rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Wells Fargo & Company reduced their target price on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating for the company in a research report on Monday, August 12th. Canaccord Genuity Group lowered their price target on Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Finally, HC Wainwright reissued a "neutral" rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th.

Institutional Trading of Ventyx Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC purchased a new position in Ventyx Biosciences in the 1st quarter worth approximately $3,437,000. Redmile Group LLC increased its position in shares of Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company's stock valued at $11,903,000 after buying an additional 1,956,923 shares during the period. Ikarian Capital LLC raised its position in shares of Ventyx Biosciences by 8,483.8% in the 1st quarter. Ikarian Capital LLC now owns 507,647 shares of the company's stock worth $2,792,000 after acquiring an additional 501,733 shares in the last quarter. Farallon Capital Management LLC bought a new stake in shares of Ventyx Biosciences during the first quarter valued at approximately $17,435,000. Finally, Opaleye Management Inc. lifted its position in Ventyx Biosciences by 12.7% during the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company's stock valued at $7,068,000 after buying an additional 145,000 shares during the period. Hedge funds and other institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Trading Up 6.9 %

Shares of Ventyx Biosciences stock traded up $0.12 on Friday, reaching $1.85. The stock had a trading volume of 2,145,864 shares, compared to its average volume of 2,032,574. The business's 50 day moving average is $2.20 and its two-hundred day moving average is $2.69. Ventyx Biosciences has a 1 year low of $1.67 and a 1 year high of $11.48. The company has a market cap of $130.81 million, a P/E ratio of -0.81 and a beta of 0.37.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.